BioCryst appoints Babar Ghias as CFO and Head of Corporate Development

BIOCRYST PHARMACEUTICALS INC

Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.
Annual base salary of $560,000; target bonus 70% of salary; one-time cash bonus of $160,000.
Inducement grants: 147,000 RSUs and options to purchase 305,000 shares, vesting over 4 years.
Ghias joins from AvenCell Therapeutics; previously EVP at Paragon Biosciences and CFO at Marathon Pharmaceuticals.
CEO Stonehouse cites Ghias' deal-making and operational experience for growth and capital deployment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.